NYSE:BHVN Biohaven Q3 2025 Earnings Report $13.21 -0.46 (-3.37%) Closing price 03:59 PM EasternExtended Trading$13.22 +0.02 (+0.12%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Biohaven EPS ResultsActual EPS-$1.64Consensus EPS -$1.91Beat/MissBeat by +$0.27One Year Ago EPSN/ABiohaven Revenue ResultsActual RevenueN/AExpected Revenue$0.34 millionBeat/MissN/AYoY Revenue GrowthN/ABiohaven Announcement DetailsQuarterQ3 2025Date11/10/2025TimeBefore Market OpensConference Call DateMonday, November 10, 2025Conference Call Time7:00AM ETUpcoming EarningsBiohaven's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Biohaven Earnings HeadlinesBiohaven's Kv7 Program Remains Key Stock Driver, UBS SaysSeptember 18, 2026 | marketscreener.comMBiohaven Rated Buy on Opakalim’s KV7 Safety Edge and Differentiated Tolerability ProfileSeptember 18, 2026 | tipranks.comMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now.September 24 at 1:00 AM | TradeSmith (Ad)Biohaven Ltd. (NYSE:BHVN) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSeptember 13, 2026 | americanbankingnews.comBiohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)September 11, 2026 | prnewswire.comBiohaven Shares Fall Premarket on Partial FDA Hold on BHV-7000September 11, 2026 | marketscreener.comMSee More Biohaven Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biohaven? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biohaven and other key companies, straight to your email. Email Address About BiohavenBiohaven (NYSE:BHVN) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and immunological disorders. The company’s research programs use a range of approaches, including small-molecule medicines, biologics and other targeted therapies, with the goal of addressing diseases that have limited or inadequate treatment options. Biohaven’s pipeline has included investigational treatments for conditions such as epilepsy, obsessive-compulsive disorder, neurodegenerative diseases, neuroinflammatory disorders and immune-mediated diseases. Its programs have included novel potassium-channel modulators, glutamate pathway therapies, brain-penetrant immune-targeting medicines and other therapies designed to act on neurological or immunological mechanisms. The company traces its origins to Biohaven Pharmaceutical, which was founded in 2013. In 2022, Pfizer acquired Biohaven’s commercial and late-stage calcitonin gene-related peptide portfolio, including the migraine products Nurtec ODT and Zavzpret, while the remaining research and development operations continued as the current Biohaven Ltd. Biohaven is headquartered in New Haven, Connecticut, and its programs are advanced through clinical development and regulatory processes in the United States and other international markets. Vlad Coric serves as the company’s chairman and chief executive officer.View Biohaven ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
